Immunotherapy and Steroids Taken for Another Condition — What Your Oncologist Needs to Know First

Yes, it can — but not equally for everyone. Steroids taken by mouth at a higher daily dose in the weeks before immunotherapy begins are the pattern linked to weaker responses in observational studies. Inhalers, skin creams, eye drops and joint injections are generally not treated the same way.

The reasoning is straightforward. Checkpoint-inhibitor immunotherapy works by releasing a brake on your own immune system. Steroids that travel through the bloodstream do the opposite — they damp that system down. Starting one while the other is already suppressing the immune response is the concern. It is a different situation from a steroid given later to treat a side effect of the treatment itself.

What the research shows is an association, not proof of cause. Patients who need a higher steroid dose before cancer treatment are often unwell for other reasons, and those reasons independently affect how well any treatment works. NCCN and ASCO guidance therefore treats an existing steroid prescription as something to plan around, not an automatic reason to withhold treatment.

Nothing on this page is a reason to change, reduce or stop a steroid you have been prescribed. Every decision described here belongs to your treating team, working with whichever specialist started the steroid in the first place.

Steroids that reach the whole body through the bloodstream — tablets, syrups and injections — are the ones your oncologist weighs. Steroids that act mainly where they are applied, such as inhalers, nasal sprays, skin creams, eye drops and most single-joint injections, are generally not counted as systemic immunosuppression.

This table describes how the question is usually approached, not a rule about your own prescription. Bring the actual strips and inhalers to your consultation, or clear photographs of them — the strength printed on the box tells your oncologist more than a remembered name does.

A low daily maintenance dose is generally accepted. A higher daily dose taken by mouth close to the start of treatment is the one clinical-trial protocols and guidelines flag. The exact cut-off is an equivalent dose your oncologist calculates from your specific prescription. It is not a number you can read off a strip.

Steroid strengths are not interchangeable. Two tablets that look identical can be several times apart in effect, which is why guidance is written as an equivalent dose rather than a plain figure on a box. Converting your prescription into that equivalent is a calculation your oncology team makes, alongside whoever prescribed it.

Duration counts as well. A short course finished several weeks ago sits differently from a dose taken continuously for two years. So does the reason: a steroid given for a cancer-related symptom is read differently from one given for a long-standing chest or joint condition. Dose, duration and reason are weighed together, never one alone.

Immunotherapy at CION is given as day care at our centres, and response-assessment PET-CT is coordinated at partner imaging centres rather than owned by us. Neither of those changes because you take steroids — but the checks scheduled around your cycles may.

Sometimes, yes. If your dose can safely come down, your oncologist will ask the specialist who prescribed it whether the lowest effective dose can be reached before treatment begins. Sometimes it cannot, and treatment goes ahead anyway with closer monitoring. This is never a change you make on your own.

Reducing a steroid is done gradually, supervised by whoever prescribed it. Stopping suddenly can allow the original condition to flare, and can leave the body unable to produce its own stress hormones — a genuine medical emergency. That risk is exactly why nobody should adjust a steroid dose because of something they have read, this page included.

Where reduction is not possible — a transplant recipient on maintenance immunosuppression, or an autoimmune condition that flares at any lower dose — the conversation changes shape. It becomes a question of whether immunotherapy is still the right choice, what the monitoring plan looks like, and what the alternatives are. That belongs in a tumour board with your other specialists' input, not in a single appointment.

There is no fixed waiting period between reducing a dose and starting treatment. Timing is set case by case by the treating team.

Because of what the immune system is doing at the time. A steroid taken before immunotherapy starts suppresses the very response the treatment is trying to switch on. A steroid given weeks later, to treat an immune-related side effect, arrives after that response has already been triggered.

This is one of the most commonly misread points in immunotherapy. Patients hear that steroids reduce the benefit and assume it applies at every stage. Current guidance does not support that reading. Steroids used to manage an immune reaction during treatment are standard care, and withholding a needed course does more harm than the theoretical effect on response.

It also means the answer changes over time. A prescription that was a planning problem before your first cycle can be entirely routine three months in. Ask your team where you stand at that point rather than assuming the first conversation still applies. The same is true much later, when the plan shifts to what comes after immunotherapy and a fresh medication review is done for the next line.

Each of these is handled differently. Inhaled steroids for asthma or COPD rarely change the plan. An autoimmune condition treated with steroid tablets needs specialist assessment and closer monitoring. A solid-organ transplant is the most complex situation, and carries a recognised risk of the transplanted organ being rejected.

• Asthma or COPD on inhalers — inhaled steroids are generally not counted as whole-body immunosuppression. Tell your team anyway: new breathlessness during immunotherapy has to be told apart from a chest flare, and knowing your usual baseline makes that far quicker.
• An autoimmune condition — rheumatoid arthritis, lupus, psoriasis, inflammatory bowel disease and autoimmune thyroid disease were excluded from most original trials, so the evidence is genuinely thinner. Guidance now supports considering treatment case by case, with the risk of a flare discussed openly beforehand.
• A solid-organ transplant — checkpoint-inhibitor treatment carries a recognised risk that the transplanted organ is rejected. This needs the transplant team and the oncology team in the same conversation before anything is decided.
• Adrenal or pituitary replacement — a replacement dose is not the same thing as an immunosuppressive dose. It is not stopped, and it is discussed as its own separate question.
• Steroids given for a cancer-related reason — for example to reduce swelling around a tumour. Here the steroid and the cancer are linked, and the plan has to account for both at once.

Being in one of these groups does not put immunotherapy off the table. It means the decision needs more than one specialist in the room, which is what a tumour board is for. Timing, dose and monitoring are all adjustable; the decision itself is not made in a hurry.

Five things, in order. None of them involves changing a medicine yourself. The aim is simply that your oncologist and the doctor who prescribed your steroid each know exactly what the other has planned.

1. 1

   Bring every medicine to the consultation

   Not a list from memory. Bring the strips, boxes and inhalers, or clear photographs of them. The printed strength matters more than the name you remember.

2. 2

   Say who prescribed each one, and why

   Your oncologist needs to know whether a steroid came from a chest physician, a rheumatologist, a transplant team or an earlier hospital admission.

3. 3

   Include everything else you take

   Blood thinners, heart medicines, diabetes tablets and thyroid medicines belong on the same list. Immunotherapy and blood thinners, heart medicines and diabetes tablets covers what changes and what does not.

4. 4

   Ask whether your dose can safely come down

   Your oncologist can raise this with the prescribing specialist. Ask for the answer in writing so both teams are working from the same plan.

5. 5

   Agree what to watch for after the first cycle

   If you take steroids for a long-term condition, agree in advance how a flare will be told apart from an immune-related side effect, and who to call when you are not sure.

Steroids are one of several combination and sequencing questions patients raise before starting. These companion pages cover the ones that come up next.

• Immunotherapy and Blood Thinners, Heart Medicines and Diabetes Tablets — the everyday prescriptions patients forget to mention, and which of them actually matter.
• The Abscopal Effect: Can Radiation Make Immunotherapy Work Better? — what is understood, and what is still theory, about combining radiation with immunotherapy.
• What Comes After Immunotherapy? Planning the Next Line — how the next line is planned if immunotherapy stops working or has to be stopped.
• Immunotherapy at CION Cancer Clinics — how immunotherapy is delivered as day care, and how patients are reviewed between cycles.

Your Full Medicine List Belongs in the Room

A 45-minute consultation leaves time to go through every prescription you already take, not just the cancer ones.